Laurus Labs Limited LAURUSLABS
Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.
Loading prices…
Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.Test a strategy on LAURUSLABS
Real prices, every charge counted. Pick one or write your own.Known mainly for antiretroviral (HIV) API manufacturing, ranking among the world's largest suppliers to global ARV drug programs, which historically left it exposed to volatile government and NGO tender pricing. The company has spent recent years diversifying into contract development and manufacturing (CDMO) for global pharma and biotech clients to reduce that dependence.
Pharma - APIs & CDMO
Active pharmaceutical ingredients (APIs), especially for HIV/antiretroviral drugs, finished dosage formulations, and contract development and manufacturing (CDMO) services where it makes drug substances and intermediates for other pharma and biotech companies.
Global generic drugmakers and international ARV drug programs buying bulk HIV APIs, plus pharmaceutical and biotech companies that outsource drug manufacturing to Laurus under CDMO contracts, not retail patients directly.
Earns on selling bulk APIs, especially ARVs, to other drugmakers and increasingly on CDMO contracts where global pharma and biotech clients pay for custom drug development and manufacturing. Profit has historically swung with ARV tender pricing, and the company is pushing to grow the steadier, higher-margin CDMO share of revenue.
Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.
EOD 13 NovThe share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.
Are its options cheap or dear?It compares the movement option prices assume with the movement the share has actually shown.
Live in market hoursImplied volatility needs the live option chain, which is open 9:15 to 3:30.
Returns and valuationWhat the market pays for this company and how well the business uses its money.
Books to 30 Sept 2026Against its sectorWhere this company ranks among similar companies on each measure.
Pharmaceuticals · 141 peers · mediansWhat the numbers sayShort plain statements about this company's latest figures.
Written by fixed rulesLatest quarterIn the quarter to September 2026 (results filed 29 Oct 2026), sales rose 33.4% from a year earlier to Rs 2,206 cr and profit rose 124.3% to Rs 436 cr.
- Debt to equity fell 2 years running (0.61 to 0.44).
- Cash from operations was at least the reported profit in each of FY24, FY25, FY26.
- Foreign institutions raised their holding by 5.1 points over 5 quarters (25.70% to 30.84%).
Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.
How the share moved on resultsWhat the share price did around each recent quarterly result.
Over the last 19 results, the share rose on 11 and fell on 8, and moved by 3% or more on 13.
Q2 FY27: results filed 29 Oct 2026. The share went from its close on 28 Oct 2026 to its close on 30 Oct 2026 +10.25%.
Dividends paidCash the company has paid per share, year by year.
2026 has paid ₹2.20 per share, about ₹91 on ₹1 lakh at today's price. Earlier years are restated to today's share count, so a bonus or split never reads as a dividend cut. Dividends are at the company's discretion and can be cut or skipped.
What it has returnedThe yearly growth rate in the share price over each period, as if it had grown smoothly.
Price only, before dividendsHeld for 5 years this compounded at +39.6% a year. The last twelve months were up +142.6%. Price only, before dividends.
Who owns itThe share of the company held by its promoters, by foreign and domestic institutions, and by the public, quarter by quarter.
Shareholding patternEach line is that holder's share of all shares over the last 6 quarters, drawn to its own scale - the printed change is the size of the move. Mutual funds and insurers sit inside the domestic figure; hover the bar above for that split.
The promoter/promoter-group stake as a percentage of total shares, each quarter since listing. A rising line means promoters are adding to their stake; a falling one often means dilution, pledge-driven sales, or stake sales to new investors.
Recent announcementsThe company's own filings to the exchange in the last six months: results, board meetings, investor calls and more, each with its source document.
Last 6 monthsAt a glanceThe eight figures most people check first, each placed against companies in the same industry.
Against its sectorPeers are the listed companies in the exchange's own industry group: Pharmaceuticals. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.
The business, year by yearSales and net profit by financial year or by quarter.
Sales and net profitWhere every ₹100 of sales goesHow each ₹100 the company sold was spent, and how much stayed as profit.
FY26In FY26, of every ₹100 of sales it kept ₹13.1 as profit. Other income added ₹0.8.
How fast it has grownCompound growth a year in sales and profit, over 3 and 5 financial years, beside the latest quarter.
Compounded a yearWhere the cash wentProfit is an accounting figure. Cash flow shows the money that really moved: in from the business, out on investments, and to or from lenders and shareholders.
From the cash flow statementIn FY26 cash rose by ₹13 Cr, after ₹1,070 Cr spent on plant and equipment.
Health check, year by yearMargins, returns and debt for each financial year, so you can see the direction.
| Measure | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Sales growthSales in this financial year against the previous one. | 22.4% | -16.6% | 10.2% | 22.7% |
| Operating marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax. | 26.4% | 15.4% | 19.0% | 26.1% |
| Net marginOf every ₹100 of sales in the year, how much was left as profit after everything. | 13.1% | 3.2% | 6.5% | 13.1% |
| ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money. | 19.6% | 4.0% | 8.2% | 17.7% |
| ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders. | 21.2% | 6.6% | 10.1% | 17.9% |
| Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings. | 0.49x | 0.61x | 0.59x | 0.44x |
| Interest coverHow many times the company's profit before interest could pay its interest bill. | 7.7x | 2.3x | 3.2x | 7.9x |
Each row against this company's own usual level: green better, red worse, grey close to it.
Peers side by sideCompanies in the same exchange-defined industry group, largest first. Tap a heading to sort.
Pharmaceuticals| Company | What the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality. | How many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit. | The share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business. | How much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money. | How much operating profit the company made on all the money in the business, whether it came from owners or lenders. | Borrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings. | Of every ₹100 of sales, how much is left as profit after all costs, interest and tax. | How much sales grew in the latest quarter against the same quarter a year earlier. | The cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share. |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | 4.51 L cr | 41.1x | 5.0x | 14.7% | 19.1% | 0.03 | 17.8% | +11.9% | 0.85% |
| DIVISLAB Divi's Laboratories Limited | 3.04 L cr | 90.3x | 16.9x | 16.2% | 21.5% | 0.00 | 27.6% | +35.4% | 0.26% |
| TORNTPHARM Torrent Pharmaceuticals Limited | 1.78 L cr | 78.9x | 9.7x | 17.0% | 15.2% | 0.76 | 12.1% | +50.8% | 0.81% |
| LAURUSLABS Laurus Labs Limited | 1.31 L cr | 97.7x | 21.6x | 17.7% | 17.9% | 0.40 | 17.0% | +33.4% | 0.09% |
| ZYDUSLIFE Zydus Lifesciences Limited | 1.19 L cr | 28.6x | 4.3x | 18.3% | 19.9% | 0.44 | 14.1% | +29.2% | 0.08% |
| DRREDDY Dr. Reddy's Laboratories Limited | 1.15 L cr | 41.1x | 3.0x | 11.5% | 13.9% | 0.15 | 8.3% | -1.5% | 0.58% |
| CIPLA Cipla Limited | 1.12 L cr | 38.8x | 3.2x | 11.7% | 16.0% | 0.01 | 10.1% | -2.4% | 0.93% |
| MANKIND Mankind Pharma Limited | 1.09 L cr | 48.6x | 6.2x | 12.4% | 12.9% | 0.30 | 14.7% | +17.3% | 0.00% |
| AUROPHARMA Aurobindo Pharma Limited | 1.05 L cr | 26.4x | 2.7x | 9.9% | 12.8% | 0.21 | 10.8% | +23.9% | 0.38% |
| LUPIN Lupin Limited | 90,557 cr | 17.4x | 3.8x | 26.9% | 28.8% | 0.23 | 17.0% | +11.1% | 0.91% |
| GLENMARK Glenmark Pharmaceuticals Limited | 74,507 cr | 51.3x | 6.7x | 14.1% | 20.4% | 0.08 | 9.2% | -31.3% | 0.09% |
| ALKEM Alkem Laboratories Limited | 61,146 cr | 29.6x | 4.1x | 17.6% | 20.6% | 0.12 | 13.4% | +13.8% | 1.04% |
| BIOCON Biocon Limited | 59,329 cr | 216.7x | 1.7x | 1.1% | 3.0% | 0.41 | 1.9% | +2.2% | 0.14% |
| ABBOTINDIA Abbott India Limited | 56,183 cr | 34.0x | - | - | - | - | 23.0% | +11.0% | 2.48% |
| GLAND Gland Pharma Limited | 55,016 cr | 44.5x | 5.2x | 10.5% | 15.0% | 0.02 | 17.5% | +23.3% | 0.60% |
| IPCALAB IPCA Laboratories Limited | 47,798 cr | 34.1x | 5.5x | 13.2% | 16.6% | 0.06 | 14.2% | +13.8% | 0.32% |
| GLAXO GlaxoSmithKline Pharmaceuticals Limited | 45,275 cr | 40.0x | 24.1x | 48.9% | 66.5% | 0.00 | 27.6% | +20.8% | 2.13% |
| EMCURE Emcure Pharmaceuticals Limited | 44,804 cr | 41.0x | 8.4x | 19.6% | 24.8% | 0.27 | 10.7% | +24.3% | 0.15% |
| AJANTPHARM Ajanta Pharma Limited | 41,037 cr | 32.5x | 8.4x | 25.4% | 32.7% | 0.02 | 20.3% | +32.5% | 0.97% |
| SAILIFE Sai Life Sciences Limited | 40,967 cr | 108.4x | 15.2x | 15.1% | 20.9% | 0.17 | 15.9% | +22.5% | 0.00% |
| ACUTAAS Acutaas Chemicals Limited | 33,069 cr | 75.3x | 17.8x | 23.5% | 31.7% | 0.00 | 27.5% | +42.7% | 0.06% |
| WOCKPHARMA Wockhardt Limited | 32,940 cr | 80.3x | 6.4x | 4.0% | 6.5% | 0.39 | 10.8% | +23.9% | 0.00% |
| PPLPHARMA Piramal Pharma Limited | 32,557 cr | - | 4.0x | -4.0% | 0.8% | 0.69 | -2.1% | +28.1% | 0.00% |
| RUBICON Rubicon Research Limited | 27,763 cr | 85.0x | 19.6x | 19.1% | 23.4% | 0.28 | 15.5% | +39.9% | 0.09% |
| NEULANDLAB Neuland Laboratories Limited | 27,043 cr | 59.8x | 13.3x | 21.4% | 27.5% | 0.17 | 19.6% | -12.6% | 0.16% |
| APLLTD Alembic Pharmaceuticals Limited | 20,249 cr | 24.0x | 3.4x | 12.4% | 11.7% | 0.25 | 9.9% | +36.3% | 1.16% |
| GRANULES Granules India Limited | 20,151 cr | 28.1x | 3.1x | 13.5% | 15.7% | 0.09 | 12.1% | +20.3% | 0.22% |
| SHILPAMED Shilpa Medicare Limited | 19,392 cr | 58.0x | 7.0x | 9.8% | 11.4% | 0.24 | 18.1% | +43.0% | 0.06% |
| ONESOURCE Onesource Specialty Pharma Limited | 18,463 cr | - | 3.1x | -1.3% | 0.4% | 0.25 | -0.1% | +37.4% | 0.00% |
| CAPLIPOINT Caplin Point Laboratories Limited | 18,157 cr | 26.4x | 4.7x | 19.9% | 24.7% | 0.00 | 29.4% | +17.9% | 0.33% |
| ERIS Eris Lifesciences Limited | 18,116 cr | 25.4x | 4.4x | 18.1% | 13.9% | 0.58 | 21.6% | +12.6% | 0.55% |
| ALIVUS Alivus Life Sciences Limited | 17,932 cr | 26.8x | 4.9x | 18.4% | 24.6% | 0.00 | 24.9% | +16.0% | 0.34% |
| PFIZER Pfizer Limited | 17,601 cr | 20.5x | 4.0x | 17.2% | 23.4% | 0.00 | 32.4% | +13.2% | 1.95% |
| COHANCE Cohance Lifesciences Limited | 17,546 cr | 509.6x | 4.5x | 5.1% | 8.0% | 0.06 | -0.3% | -14.2% | 0.00% |
| NATCOPHARM Natco Pharma Limited | 15,898 cr | 12.7x | 1.7x | 16.9% | 17.1% | 0.08 | 32.9% | -44.7% | 0.56% |
| JUBLPHARMA Jubilant Pharmova Limited | 15,356 cr | 43.4x | 2.2x | 6.0% | 8.7% | 0.45 | 4.1% | +17.3% | 0.52% |
| ASTRAZEN AstraZeneca Pharma India Limited | 15,079 cr | 84.8x | 17.2x | 22.8% | 31.2% | 0.00 | 6.8% | +30.4% | 0.60% |
| MARKSANS Marksans Pharma Limited | 14,437 cr | 25.8x | 4.3x | 25.4% | 35.1% | 0.01 | 16.7% | +30.5% | 0.28% |
| CORONA CORONA Remedies Limited | 14,248 cr | 68.8x | 17.7x | 24.8% | 27.8% | 0.12 | 13.3% | +22.2% | 0.43% |
| CONCORDBIO Concord Biotech Limited | 12,428 cr | 44.5x | 6.0x | 13.5% | 17.9% | 0.00 | 23.9% | +25.1% | 0.63% |
Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.
Month by monthThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.
Price return each month| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -12.9 | +11.5 | -7.7 | +10.9 | +23.7 | +11.4 | +19.6 | +5.4 | +3.4 | +21.5 | -0.2 | · | +116.6% 11m |
| 2025 | -3.1 | -9.7 | +16.4 | -1.6 | +0.9 | +18.9 | +20.6 | -2.0 | -1.8 | +13.3 | +8.2 | +7.4 | +83.8% |
| 2024 | -11.4 | +6.5 | -3.4 | +14.7 | -6.9 | +1.3 | +9.3 | +1.4 | -1.4 | +6.0 | +15.4 | +6.3 | +40.1% |
| 2023 | -12.0 | -4.8 | -6.8 | +5.0 | +7.5 | +10.9 | -4.0 | +13.5 | -1.1 | -8.5 | +5.3 | +13.0 | +14.6% |
| 2022 | -6.7 | +7.7 | +9.0 | -1.1 | -2.7 | -18.1 | +12.5 | +10.8 | -11.4 | -11.4 | -8.2 | -10.1 | -30.4% |
| 2021 | -2.2 | +1.4 | +3.4 | +25.1 | +15.7 | +31.5 | -6.8 | +3.9 | -7.5 | -16.3 | -1.4 | +6.0 | +52.6% |
| 2020 | +19.6 | -3.9 | -21.5 | +57.8 | -8.6 | +10.9 | +79.7 | +21.4 | +26.7 | +11.2 | -0.8 | +11.5 | +390.8% |
| 2019 | -2.4 | -9.9 | +19.8 | -4.3 | -5.7 | -6.6 | -0.2 | -2.1 | +13.9 | -1.2 | -5.3 | +2.7 | -5.2% |
| 2018 | -4.8 | +5.2 | -7.5 | +1.7 | -7.7 | -2.1 | -1.6 | -3.6 | -1.3 | -21.2 | +12.7 | -1.2 | -30.1% |
| 2017 | -1.3 | +7.4 | +1.2 | +0.7 | +10.1 | +7.5 | -5.6 | -9.2 | -3.8 | +6.2 | -2.4 | +3.3 | +12.9% |
Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.
Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.
| Date | Party | Side | Quantity | Price | Value |
|---|---|---|---|---|---|
| 2026-08-31 | BNP PARIBAS FINANCIAL MARKETS · bulk | SELL | 62,72,175 | ₹1,914.28 | ₹1,200.67 Cr |
| 2026-08-31 | INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD. · bulk | SELL | 51,34,361 | ₹1,914.04 | ₹982.74 Cr |
| 2026-08-31 | SOCIETE GENERALE · bulk | SELL | 28,10,437 | ₹1,903.84 | ₹535.06 Cr |
| 2026-08-31 | BNP PARIBAS FINANCIAL MARKETS · bulk | BUY | 15,399 | ₹1,860.35 | ₹2.86 Cr |
| 2026-08-31 | INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD. · bulk | BUY | 1,718 | ₹1,922.69 | ₹0.33 Cr |
| 2025-01-27 | GRAVITON RESEARCH CAPITAL LLP · bulk | BUY | 36,90,709 | ₹536.50 | ₹198.01 Cr |
| 2025-01-27 | GRAVITON RESEARCH CAPITAL LLP · bulk | SELL | 36,89,009 | ₹536.23 | ₹197.82 Cr |
| 2023-03-14 | CYBAGE SOFTWARE PRIVATE LIMITED · block | SELL | 6,35,894 | ₹305.00 | ₹19.39 Cr |
- Press releasePress Release29 Oct 2026
Laurus Labs Limited has informed the Exchange regarding a press release dated October 29, 2026, titled "Press Release on the Financial Results for the quarter and half-year ended September 30, 2026 along with the acquisition of Galenvs Sciences.".
- Board outcomeOutcome of Board Meeting29 Oct 2026
Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
- Board outcomeOutcome of Board Meeting24 Jul 2026
Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
- Board outcomeOutcome of Board Meeting30 Apr 2026
Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
- Press releasePress Release23 Jan 2026
Laurus Labs Limited has informed the Exchange regarding a press release dated January 23, 2026, titled "Press Release on the Unaudited Financial Results for the quarter and nine-months endedDecember 31, 2025".
- Board outcomeOutcome of Board Meeting23 Jan 2026
Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
- Board outcomeOutcome of Board Meeting23 Oct 2025
Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
- Board outcomeOutcome of Board Meeting25 Jul 2025
Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
- Integrated Filing- Financial24 Jan 2025
Please see annexed enclosure.
- Financial Result Updates24 Jan 2025
Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
The last two years of the company's filings to the exchange, grouped by the exchange's own categories. Each opens the original document.
Read enough? Test LAURUSLABS. “Buy LAURUSLABS when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.
Run it free